HTL Biotechnology, Market Leader in Biopolymers, Acquires the Modern Meadow’s Human Recombinant Collagen Platform for Beauty and Biomedical Applications

HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow (Nutley, NJ). Notably, this acquisition includes Modern Meadow’s platform of recombinant proteins, with the most advanced product being human recombinant collagen type III (rhCOL3). HTL Biotechnology’s ambition, through this acquisition, is to drive innovation in the company’s historical segments, including aesthetic medicine, rheumatology, and ophthalmology, as well as explore new therapeutic areas.

Read the full article: HTL Biotechnology, Market Leader in Biopolymers, Acquires the Modern Meadow’s Human Recombinant Collagen Platform for Beauty and Biomedical Applications //

Source: https://www.prnewswire.com/news-releases/htl-biotechnology-market-leader-in-biopolymers-acquires-the-modern-meadows-human-recombinant-collagen-platform-for-beauty-and-biomedical-applications-302135891.html

Leave a Comment

Your email address will not be published.

Scroll to Top